食管鳞癌新辅助放化疗中68Ga-FAPI与18F-FDG PET/CT的时空体素一致性及其与病理缓解的关联
本研究基于48例食管鳞癌患者的前瞻性试验回顾分析,在术前和放化疗后分别行68Ga-FAPI与18F-FDG PET/CT,通过体素相关性分析评估肿瘤代谢与成纤维细胞活性的时空一致性。结果显示放化疗前双示踪剂摄取强相关(SUV_R=0.80±0.17),治疗后减弱(SUV_R=0.51±0.23);整合治疗后SUV_R与FDG的SUV_CV的Logistic模型可显著预测病理缓解(p=0.007,AUC=0.78,95%CI 0.62-0.95)。
要点
- 放化疗前FAPI与FDG摄取呈强空间相关,治疗后相关性减弱。
- 治疗后SUV_R联合FDG的SUV_CV可预测病理缓解,AUC为0.78。
- 剂量反应矩阵相关性高(DRM_R=0.82±0.14),提示治疗敏感性空间一致。
核心结论
- 放化疗前FDG或FAPI PET构建的肿瘤体素强度与剂量反应呈现强空间相关。
- 探索性分析中,治疗后FAPI-FDG相关系数联合FDG的SUV_CV与病理缓解相关。
研究设计与样本
- 回顾性分析前瞻性试验(ChiCTR2100051599)中48例食管鳞癌患者。
- 患者在放化疗前后均行68Ga-FAPI与18F-FDG PET/CT,采用体素相关性分析。
主要发现
- 放化疗前FAPI与FDG摄取强相关(S1 SUV_R=0.80±0.17),放化疗后减弱(S2 SUV_R=0.51±0.23)。
- 两个剂量反应矩阵强相关(DRM_R=0.82±0.14)。
- 整合治疗后SUV_R与SUV_CV_FDG的二元Logistic模型显著预测病理缓解(p=0.007),优化校正AUC为0.78(95%CI 0.62-0.95)。
关键数值与推荐
- SUV_R用于量化静态摄取一致性,DRM_R用于量化治疗剂量敏感性一致性。
- 常规参数包括SUVmax、SUVmean、SUV_CV、SUVmaxratio、SUVmeanratio、DRMmax、DRMmedian、DRM_CV及耐药肿瘤体积V(DRM>0.7)。
- 除DRM相关指标外,其余指标与病理肿瘤退缩分级(TRG)的关联为探索性评估。
临床怎么用
- 双示踪剂PET/CT体素相关性分析可能辅助评估食管鳞癌新辅助放化疗的病理缓解。
- 治疗后FAPI-FDG相关系数联合FDG的SUV_CV或可作为预测病理缓解的探索性指标。
局限性
- 本研究为回顾性分析,样本量48例。
- 与病理缓解的关联分析为探索性,除DRM相关指标外。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to investigate the spatiotemporal correlation between tumor metabolism and cancer-associated fibroblast activity using dual-tracer PET/CT, and to explore their potential association with pathologic response to neoadjuvant chemoradiotherapy (nCRT) in esophageal squamous cell carcinoma (ESCC). METHODS: This retrospective analysis of a prospective trial (ChiCTR2100051599) included 48 patients with ESCC from February 2022 to August 2024. All patients underwent 68Ga-FAPI and 18F-FDG PET/CT before pre-nCRT (S1) and after nCRT (S2). Two primary metrics were used to quantify their spatial correlations by voxel-wise correlation analyses: the SUV Correlation Coefficient (SUV_R), reflecting static uptake concordance, and the Dose-Response Matrix Correlation Coefficient (DRM_R), reflecting concordance in treatment dose sensitivity. The conventional parameters derived from FAPI- and FDG- PET were also extracted: SUVmax, SUVmean, SUV_CV, SUVmaxratio, SUVmeanratio, DRMmax, DRMmedian, DRM_CV and the resistant tumor volume (V(DRM> 0.7)). The associations of these metrics with pathological tumor regression grade (TRG) were evaluated in an exploratory manner, except for DRM-related metrics. RESULTS: A strong voxel-wise correlation was observed between pre-nCRT FAPI and FDG uptake (S1 SUV_R = 0.80 ± 0.17), which was weaker after nCRT (S2 SUV_R = 0.51 ± 0.23). Two dose-response matrices showed a strong correlation (DRM_R = 0.82 ± 0.14). The bivariate Logistic model, integrating the post-treatment SUV_R and SUV_CV_FDG, significantly predicted pathological response (p = 0.007), achieving an optimization-corrected AUC of 0.78 (95%CI: 0.62-0.95). CONCLUSION: The pre-nCRT tumor voxel intensity and dose response constructed using either FDG or FAPI PET imaging exhibited a strong spatial correlation. In this exploratory analysis, the post-nCRT FAPI-FDG correlation coefficient was associated with pathologic response when combined with SUV_CV_FDG in a Logistic model.
引用
- Dai J, Yang L, Wang H, et al. Spatiotemporal voxel-wise concordance between 68Ga-FAPI and 18F-FDG PET/CT: association with pathologic response in esophageal squamous cell carcinoma receiving neoadjuvant chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2026. PMID: 42118324. doi:10.1007/s00259-026-07910-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。